Пресс-Центр

Пресс-релизы

Предыдущий

Следующий

Dec

Dr. Reddy's Announces Final Approval of Ondansetron Tablets with 180 Days of Marketing Exclusivity
Perlecan Pharma moves Dr. Reddy's novel anti-diabetic drug candidate to Phase I clinical trial
Dr. Reddy's Teams Up With University of Aukland for World's First Polypill Trial

Nov

Dr. Reddy's Announces Issuance of Additional American Depositary Shares
Dr. Reddy’s and Torrent Pharma Sign Agreement For Exclusive Commercialization Of Listril And Listril Plus In Russia
Dr. Reddy's announces pricing of American Depository Shares
Dr. Reddy's files F-3 registration statement with the U.S. Securities and exchange commission

Oct

Sep

Jul

Jun

May

Jan

Dr. Reddy's launches Supanac® - (Diclofenac potassium)